Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
Healthcare
$14.16 +1.49%
+$0.37 today
- Market cap
- $1.25B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
52W Low $12.59High $47.65
Volume 1.17M
Average 1.48M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$170.60M
FY 2025 · Annual
Net Income
-$154.65M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 16.31M | 26.25M | 70.36M | 168.58M | 132.01M |
| Selling, General & Admin | 2.42M | 5.23M | 14.3M | 23.82M | 38.6M |
| Operating Expenses | 18.73M | 31.48M | 84.66M | 192.4M | 170.6M |
| Depreciation & Amortization | 0 | 0 | 0 | 43K | 59K |
| EBITDA | (19.38M) | (28.12M) | (71.9M) | (177.77M) | (154.59M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.73M) | (31.48M) | (84.66M) | (192.4M) | (170.6M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.68M | 12.76M | 14.59M | 15.95M |
| Interest Expense | 27K | 1.68M | 0 | 0 | 0 |
| Other Income / Expenses | (683K) | 1.68M | 12.76M | 14.59M | 15.95M |
| Income Before Tax | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| EPS (Diluted) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| 4.98M | 5.17M | 36.19M | 48.54M | 67.66M | |
| 4.98M | 5.17M | 36.19M | 48.54M | 67.66M |
MLYS Earnings Waterfall · TTM
NASDAQ:MLYS · Revenue to Net Income
Key Ratios
EPS$-4.24
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-14.4
P/S Ratio0.0
Analysis
$0 of revenue converted into -$349.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.24, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Oct 29, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 20, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 20, 2026 |
How much revenue does MLYS generate?
Mineralys Therapeutics, Inc. (MLYS) reported $0.00 of revenue in fiscal 2025.
Is MLYS profitable?
Mineralys Therapeutics, Inc. (MLYS) reported -$154.65M of net income.
Continue the stock analysis
Jump to another research area for this company.